Listen Now

In this podcast episode, Samuel Klempner, MD, and Gregory Botta, MD, PhD, provide expert commentary on the rationale and development of novel agents under investigation for targeting claudin 18.2 in gastric and gastroesophageal cancers, with topics including: Expression patterns and function of the claudin family of proteins in normal gastric tissues Biologic rationale for utility of claudin 18.2 as an actionable therapeutic target in oncology Prognostic implications of claudin 18.2 overexpression in gastric and gastroesophageal cancers Laboratory methodology involved in claudin 18.2 scoring as a potential predictive biomarker for patient selection Future directions for clinical development of agents targeting claudin 18.2, including monoclonal antibodies, bispecific antibodies, antibody‒drug conjugates, and CAR T-cell constructs Presenters: Samuel Klempner, MDAssociate ProfessorDepartment of MedicineDivision of Hematology-OncologyMass General Cancer CenterHarvard Medical SchoolBoston, Massachusetts Gregory Botta, MD, PhDClinical Professor of MedicineDepartment of MedicineDivision of Hematology & OncologyUniversity of California San DiegoLa Jolla, California Content for this program was supported by educational grants from Astellas and Bristol Myers Squibb. Link to the full program, including a CME-certified text module, downloadable slideset, and ClinicalThought (coming soon!):bit.ly/3lQxPrq

In this podcast episode, Prithviraj Bose, MD, and Andrew Kuykendall, MD, discuss their contemporary approaches to the treatment of patients with essential thrombocythemia.  The topics covered include: When to use cytoreduction therapies and which therapies to use in low-risk patients Type 1 and type 2 CALR mutations and addressing patient concerns with data from sequencing reports Experts’ thoughts on therapy options in higher-risk patients Presenters: Prithviraj Bose, MD Associate ProfessorDivision of Cancer MedicineDepartment of LeukemiaThe University of TexasMD Anderson Cancer CenterHouston, Texas Andrew Kuykendall, MDAssistant Professor Department of Oncologic SciencesUniversity of South FloridaAssistant MemberMalignant HematologyH. Lee Moffitt Cancer CenterTampa, Florida  Content for this program was supported by educational grants from GSK, Incyte Corporation, and PharmaEssentia Corp. Link to the full program, including downloadable slides and an on-demand webcast from the live event:bit.ly/3XF3cSF

In this episode, Daniel J. DeAngelo, MD, PhD; Kjeld Schmiegelow, MD, DMSci; and Emily Curran, MD, answer key questions asked by the audience during a live satellite symposium at the 2022 American Society of Hematology Annual Meeting on optimizing pediatric or pediatric-inspired regimens containing asparaginase for the treatment of young and older adults with acute lymphoblastic leukemia. Topics discussed include: Practical considerations for management of allergy-like reactions and hypersensitivity to asparaginase Indirect methods for measuring asparaginase activity Strategies to mitigate adverse events with asparaginase treatment, including hepatotoxicity, pancreatitis, and thrombosis Considerations for use of asparaginase in special populations (eg, high BMI, older age) Presenters: Program DirectorDaniel J. DeAngelo, MD, PhDProfessor of MedicineDepartment of MedicineHarvard Medical SchoolChief of the Division of LeukemiaDepartment of Medical OncologyDivision of Hematologic MalignanciesDana‐Farber Cancer InstituteBoston, Massachusetts Emily Curran, MDAssistant ProfessorDivision of Hematology/OncologyUniversity of Cincinnati Cancer InstituteCincinnati, Ohio Kjeld Schmiegelow, MD, DMSciProfessorDepartment of Pediatric OncologyRighospitalet University HospitalCopenhagen, Denmark Content based on an online CME program supported by an independent educational grant from Jazz Pharmaceuticals. Link to full program:http://bit.ly/3YXkLyj  

In this podcast episode, Steven M. Horwitz, MD; Pamela B. Allen, MD, MSc; and Kerry Savage, MD, MSc, answer questions from an audience of healthcare professionals on topics related to the management of T-cell lymphomas, including: Use of brentuximab vedotin in ≤1% CD-30‒expressing lymphomas Strategies with JAK inhibition and epigenetic agents Allogeneic transplantation in cutaneous T-cell lymphoma Presenters: Steven M. Horwitz MDMember, Memorial Sloan Kettering Cancer Center Attending Physician, Memorial HospitalProfessor of Medicine, Weill Cornell Medical College New York, New York Pamela B. Allen, MD, MScAssistant ProfessorDepartment of Hematology/OncologyEmory University, Winship Cancer InstituteThe Emory ClinicAtlanta, Georgia Kerry Savage MD, MScProfessor of Medicine University of British ColumbiaMedical OncologistDivision of Medical OncologyBC Cancer Vancouver, British Columbia, Canada Content for this program was supported by educational grants from Daiichi Sankyo; Kyowa Kirin, Inc.; and Seagen Inc.  Link to the full program, including downloadable slides, expert commentary, and an on-demand webcast:bit.ly/3ItqEOd

In this podcast, Rami Komrokji, MD; María Díez Campelo, MD, PhD; and Amer Zeidan, MBBS, MHS answer questions from an audience of healthcare professionals on topics related to personalized management of myelodysplastic syndromes including:   Practical use of the Molecular International Prognostic Scoring System   Mutational targets and other treatments in ongoing clinical trials Prophylaxis with venetoclax therapy Best practices for bone marrow transplant, including induction and salvage regimens Treatment options for hypoplastic myelodysplastic syndromes Presenters:Rami Komrokji, MDProfessorDepartment of Oncologic SciencesUniversity of South Florida  Vice ChairMalignant Hematology DepartmentMoffitt Cancer CenterTampa, Florida María Díez Campelo, MD, PhDAssociate ProfessorDepartment of MedicineSchool of MedicineUniversity of SalamancaHematologistDepartment of HematologyUniversity Hospital of SalamancaSalamanca, Spain Amer Zeidan, MBBS, MHSAssociate Professor, Internal MedicineHematologyLeader, Leukemia and Myeloid Disease Aligned Research Team (DART)Director, Hematology Early Therapeutics ResearchYale Cancer Center and Smilow Cancer HospitalYale University School of MedicineNew Haven, Connecticut Link to full program, including downloadable slidesets, expert commentaries, and on-demand webcast:http://bit.ly/3YXgKK3    

In this podcast episode from a live CCO Cancer Conversations webinar, Mark Pegram, MD, and Sara Tolaney, MD, MPH, provide expert perspectives on optimal treatment strategies for patients with triple-negative breast cancer (TNBC), with topics including: Current data and strategies for using PD-1/PD-L1 inhibitors in early-stage TNBC  Clinical implications of PD-L1 status on therapeutic planning for patients with metastatic TNBC  Current data and treatment strategies and the future of antibody–drug conjugates in the management of relapsed/refractory advanced TNBC  Treatment implications of the presence of BRCA1/2 mutations and homologous recombination deficiency genes in advanced TNBC Role of PARP inhibitors in the treatment of TNBC Presenters:  Mark Pegram, MDProfessor Medical OncologyStanford UniversityPalo Alto, California Sara Tolaney, MD, MPHAssociate Professor of MedicineDivision of Breast OncologyHarvard Medical SchoolChief, Division of Breast OncologyBreast Oncology ProgramDana-Farber Cancer InstituteBoston, Massachusetts Content based on an online CME/CE/CPE program supported by educational grants from Gilead Sciences, Inc. Link to full program:http://bit.ly/3iQzDz5

In this podcast episode, Raajit Rampal, MD, PhD, and Brady L. Stein, MD, MHS, discuss their contemporary approaches to the treatment of patients with polycythemia vera. The topics covered include: Patient presentation and goals of frontline therapy Considerations for second-line therapy in the setting of treatment intolerance Experts’ thoughts on the potential of early intervention to alter disease progression Presenters: Raajit Rampal, MD, PhDAssociate MemberAssociate Attending PhysicianLeukemia ServiceDepartment of MedicineMemorial Sloan Kettering Cancer CenterNew York, New York Brady L. Stein, MD, MHSProfessor of MedicineDepartment of Hematology/OncologyNorthwestern University Feinberg School of MedicineChicago, Illinois Content for this program was supported by educational grants from GSK, Incyte Corporation, and PharmaEssentia Corp. Link to the full program, including downloadable slides and an on-demand webcast from the live event:https://bit.ly/3X3x6jX

In this episode, David Kaplan, MD, MSc, and Tamar Taddei, MD, discuss which patients should be screened for hepatocellular carcinoma, current surveillance recommendations, barriers to implementation, emerging biomarkers in development, and unmet needs in hepatocellular carcinoma surveillance.  Presenters: David E. Kaplan, MD, MScAssociate ProfessorPerelman School of MedicineChief, Hepatology Section Division of Gastroenterology and Hepatology University of PennsylvaniaDirector of HepatologyCorporal Michael J. Crescenz VA Medical CenterPhiladelphia, Pennsylvania Tamar Taddei, MDProfessor Section of Digestive Diseases Department of Internal MedicineYale School of Medicine Chief, GI Section VA Connecticut Healthcare SystemWest Haven, Connecticut

In this episode, Zoe Lanham, a woman with high-risk hormone receptor–positive/HER2-negative early breast cancer, discusses the importance of effective communication between patients and their healthcare team, drawing on her personal experience.  Presenter: Zoe LanhamPatient Link to full program:https://bit.ly/3Fukjzk

In this episode, Prof Isabelle Ray Coquard, MD, PhD, and Ignace Vergote, MD, PhD, share their thoughts on key studies of interested presented at the 2022 ESGO annual meeting in Berlin, Germany, including: • Phase III CALLA trial of durvalumab combined with and following chemoradiotherapy in locally advanced cervical cancer   • Geneva HRD test: validation of samples from PAOLA-1 dataset using Geneva laboratory–developed test   • Validation of NOGGO-GIS HRD assay using samples from the PAOLA-1 trial   • Survival results from phase III ARIEL3: maintenance rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer Presenters: Isabelle Ray-Coquard, MD, PhDProfessor of Department of Medical OncologyClinical Science Institute of the Léon Bérard CenterLyon, France   Ignace Vergote, MD, PhDProfessor Em. of Department of Obstetrics and Gynecologic OncologyUniversity Hospitals LeuvenLeuven, Belgium Content supported by educational grants from AstraZeneca, GlaxoSmithKline, Karyopharm Therapeutics, and Merck Sharp & Dohme Corp. Link to full program, including a downloadable highlights slideset, and ClinicalThought commentaries: https://bit.ly/3SSSqpN  

In this episode, activist and breast cancer survivor Yee Won Chong shares his experience as a transmasculine person navigating the healthcare system with Norma Steiner, MD, a gynecologic oncologist, who in turn offers her perspective on caring for patients across the gender spectrum. Topics include: 4 aspects of transgender care: emotional, social, medical, legal Getting language right and how to gracefully recover from fumbles Sensitively approaching ongoing cancer care in transmasculine and transfeminine individuals Handling billing and charting challenges when caring for transgender patients Ideas for institutional change to improve healthcare for transgender individuals Presenters: Yee Won ChongCo-filmmaker, Trans Dudes with Lady CancerSenior Fellow, Racial EquityWestern States CenterEquity, Diversity, and Inclusion Strategist and ConsultantPortland, Oregon Norma Steiner, MDGynecological OncologistNorthwest PermanentePortland, Oregon Link to full program:http://bit.ly/3Ugz0LR

In this episode, Farrukh T. Awan, MD, and Nicole Lamanna, MD, answer questions from an audience of healthcare professionals on topics related to the use of BTK inhibitors for the management of chronic lymphocytic leukemia (CLL). The topics covered include: Whether it is justifiable to use chlorambucil plus obinutuzumab as a control arm in a registrational trial today Relevance of overall response rate vs progression-free survival for BTK inhibitor therapy Approval of ibrutinib/venetoclax combination therapy for patients with CLL Key differences between zanubrutinib and acalabrutinib in the treatment of patients with CLL How to transition/overlap next therapy in patients with CLL with progression while receiving a BTK inhibitor Faculty:Farrukh T. Awan, MDAssociate Professor of Internal MedicineDirector of Lymphoid Malignancies ProgramHarold C. Simmons Comprehensive Cancer CenterUniversity of Texas Southwestern Medical CenterDallas, Texas Nicole Lamanna, MDAssociate ProfessorLeukemia ServiceDirector of CLL ProgramHematologic Malignancies SectionDepartment of MedicineNew York-Presbyterian/Columbia University Medical CenterNew York, New York Link to the complete program, including downloadable slidesets and an on-demand webcast:https://bit.ly/3EjvSKm

In this episode, Christopher R. Flowers, MD, MS, and Kami Maddocks, MD, discuss their choices of recent important trials presented at the Society of Hematologic Oncology 2022 Annual Meeting evaluating the use of BTK inhibitors in chronic lymphocytic leukemia and mantle cell lymphoma. The discussion includes analyses of: GLOW: phase III randomized trial of ibrutinib plus venetoclax vs chlorambucil plus obinutuzumab for older or unfit patients with previously untreated chronic lymphocytic leukemia  BRUIN: phase I/II study of pirtobrutinib for previously treated mantle cell lymphoma (including previous BTK inhibitor) Presenters: Christopher R. Flowers, MD, MSDepartment Chair, Department of Lymphoma/MyelomaDivision of Cancer MedicineUniversity of Texas MD Anderson Cancer Center Houston, Texas Kami Maddocks, MDProfessor of Clinical Internal MedicineDivision of Internal MedicineDepartment of HematologyThe Ohio State UniversityLymphoma Program DirectorThe Ohio State University James Cancer HospitalColumbus, Ohio

In this episode,Susana Banerjee, MBBS, MA, PhD, and Mansoor Raza Mirza, MD, share their thoughts on key studies of interested presented at the IGCS 2022 Annual Global Meeting for ovarian and cervical cancers including: Post-hoc analyses from SOLO-3: olaparib vs physician’s choice chemotherapy in germline BRCA mutant platinum-sensitive recurrent ovarian cancer Phase III CALLA trial: durvalumab combined with and following chemoradiation for locally-advanced cervical cancer Phase III ARIEL3: final OS for maintenance rucaparib vs placebo following response to platinum-based chemotherapy for recurrent high-grade serous ovarian cancer Retrospective NeCTuR study: outcomes with topotecan, paclitaxel, and bevacizumab (TPB) vs non-TPB regimens for recurrent high-grade neuroendocrine carcinoma of the cervix Presenters: Susana Banerjee, MBBS, MA, PhD, FRCPConsultant Medical Oncologist and Research LeadGynaecology UnitRoyal Marsden NHS Foundation TrustLondon, United Kingdom Mansoor Raza Mirza, MDChief OncologistDepartment of OncologyRigshopitalet – Copenhagen University HospitalCopenhagen, Denmark Content supported by educational grants from AstraZeneca, GlaxoSmithKline, Karyopharm Therapeutics, and Merck Sharp & Dohme Corp. Link to full program, including a downloadable highlights slideset, and ClinicalThought commentaries:https://bit.ly/38xuRBv

In this podcast episode from Clinical Care Options, Paul G. Richardson, MD; Natalie S. Callander, MD; and Noopur Raje, MD, answer questions from a live webinar on therapeutic options currently available for patients with relapsed/refractory multiple myeloma. The topics covered include: How to sequence currently available therapies after relapse Challenges with using BCMA-targeted agents in clinical practice Experts’ thoughts on the potential approval of bispecific agents Presenters include: Paul G. Richardson, MDRJ Corman Professor of MedicineHarvard Medical SchoolClinical Program LeaderDirector of Clinical ResearchJerome Lipper Multiple Myeloma CenterDana Farber Cancer InstituteBoston, Massachusetts Natalie S. Callander, MDProfessor of MedicineSchool of Medicine and Public HealthUniversity of WisconsinDirectorMyeloma Clinical ProgramUniversity of Wisconsin Carbone Cancer CenterMadison, Wisconsin Noopur Raje, MDDirectorCenter for Multiple MyelomaMassachusetts General Hospital Cancer CenterProfessor of MedicineHarvard Medical SchoolBoston, Massachusetts Content for this program was supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Karyopharm Therapeutics Inc.; and Regeneron Pharmaceuticals, Inc. Link to the full program, including downloadable slides and an on-demand webcast from the live event:https://bit.ly/3Fc7eMK

In this episode, Domenica Lorusso, MD, PhD, and Alexandra Leary, MD, PhD, provide their expert insights on key updates presented for ovarian cancer trials including: Phase III GOG-3004/SOLO-1: OS results after 7 years of follow-up for patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib vs placebo Phase III ENGOT-ov25/PAOLA-1: final OS results from the trial of maintenance therapy with olaparib with bevacizumab vs bevacizumab alone in women with newly diagnosed advanced ovarian cancer Phase III ATHENA-MONO: outcomes by disease subgroups receiving rucaparib vs placebo maintenance after platinum-based chemotherapy in patients with newly diagnosed advanced ovarian cancer Phase III ARIEL4: OS outcomes following treatment with rucaparib vs chemotherapy in patients with relapsed advanced ovarian cancer and a deleterious BRCA1/2 mutation Presenters: Domenica Lorusso, MD, PhDAssociate ProfessorGynecologic Oncology DepartmentClinical Research UnitFondazione Policlinico Gemelli IRCCSRome, Italy Alexandra Leary, MD, PhDMedical Oncologist and Team LeaderGynecology Translational Research LabDepartment of MedicineGustave Roussy Cancer CenterParis, France Content supported by educational grants from AstraZeneca, GlaxoSmithKline, Karyopharm Therapeutics, and Merck Sharp & Dohme Corp. Link to full program, including a downloadable highlights slideset, and ClinicalThought commentaries: https://bit.ly/3SSSqpN

In this episode, Ryan D. Gentzler, MD, MS, and Jonathan Riess, MD, MS, answer audience questions on managing EGFR-mutated non-small-cell lung cancer (NSCLC) from a live meeting series. The episode includes expert insights on: • Identifying patients who may benefit the most from adjuvant osimertinib   • Testing for EGFR mutations in early-stage NSCLC • Critical importance of getting molecular test results before starting immunotherapy • Monitoring cardiac toxicity in patients receiving osimertinib • Key ongoing trials in EGFR-mutated NSCLC for patients with newly diagnosed disease and following progression on osimertinib Presenters: Ryan D. Gentzler, MD, MSAssociate ProfessorDivision of Hematology/OncologyDepartment of MedicineUniversity of VirginiaThoracic Medical OncologistUniversity of Virginia Comprehensive Cancer CenterCharlottesville, Virginia Jonathan Riess, MD, MSAssociate ProfessorDepartment of Internal Medicine/Hematology-OncologyUniversity of California, DavisMedical Director, Thoracic OncologyUniversity of California, Davis Comprehensive Cancer CenterSacramento, California Link to full program: https://bit.ly/3DZGzSO   

In this episode, Julie M. Vose, MD, MBA, and Matthew S. Davids, MD, MMSc, discuss their choices of recent important trials presented at the Pan Pacific Lymphoma Conference 2022 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion includes analyses of:  BRUIN (CLL/small lymphocytic lymphoma [SLL]): phase I/II study of pirtobrutinib for previously treated CLL (including previous BTK inhibitor) SEQUOIA: phase III study evaluating cohort 1 of zanubrutinib vs bendamustine/rituximab in untreated CLL/SLL without del(17p) MAJIC: phase III trial in progress of acalabrutinib + venetoclax vs venetoclax + obinutuzumab in previously untreated CLL BRUIN (MCL): phase I/II study of pirtobrutinib for previously treated MCL (including previous BTK inhibitor) BRUIN MCL-321: phase III trial in progress of pirtobrutinib vs investigator’s choice acalabrutinib, ibrutinib, or zanubrutinib in previously treated, BTK inhibitor–naive MCL BRIDGE: series case report from phase II study evaluating zanubrutinib-based induction and maintenance in young patients with MCL Presenters:  Julie M. Vose, MD, MBAChief, Division of Oncology and HematologyNeumann M. and Mildred E. Harris ProfessorDepartment of Internal MedicineUniversity of Nebraska Medical CenterOmaha, Nebraska Matthew S. Davids, MD, MMScAssociate Professor of MedicineHarvard Medical SchoolDirector of Clinical ResearchDivision of LymphomaDana-Farber Cancer InstituteBoston, Massachusetts Link to full program:https://bit.ly/3OQ6634

In this podcast episode from Clinical Care Options (CCO), Heinz-Josef Klumpen, MD, PhD, and Chris Verslype, MD, PhD, discuss challenges in selecting and sequencing therapy for patients with advanced hepatocellular carcinoma. Topics include: Factors to consider before selecting frontline immunotherapy Role of TKIs in the frontline Impact of Child-Pugh status on the efficacy of immunotherapy/VEGF inhibitor combination therapy Real-world evidence on frontline immunotherapy/VEGF combination therapy Factors to consider when selecting second-line therapy including the role of TKIs and planning for multiple lines of therapy Presenters: Heinz-Josef Klumpen, MD, PhDStaff Specialist, Medical OncologistDepartment of Medical OncologyAmsterdam UMCAmsterdam, The Netherlands Chris Verslype, MD, PhDProfessorClinical Digestive OncologyKULeuvenHead of ClinicHepatologyDigestive OncologyU.Z. LeuvenLeuven, Belgium

In this episode, Erika P. Hamilton, MD, and Komal Jhaveri, MD, discuss their approaches to and key studies for current management of patients with HER2-positive breast cancer. The discussion includes:  Optimizing systemic therapy for patients with HER2-positive early breast cancer based on disease characteristics and risk Sequencing available therapies for patients with HER2-positive metastatic disease, including new data on first- and second-line therapy and how to manage patients with central nervous system metastases Managing common adverse events associated with HER2-targeted therapy Presenters: Erika P. Hamilton, MDDirector, Breast and Gynecologic Cancer Research ProgramDrug Development UnitSarah Cannon Research InstituteInvestigatorTennessee OncologyNashville, Tennessee Komal Jhaveri, MDAssistant Professor of MedicineWeill Cornell Medical CollegeAssociate Attending PhysicianBreast Medicine ServiceDepartment of MedicineMemorial Sloan Kettering Cancer CenterNew York, New York Follow along with Podcast Pearls slideset:https://bit.ly/3eMqxB8 See full program:  https://bit.ly/3oBdd45